Skip to main content

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease

Objective

CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

Call for proposal

H2020-SC1-2016-2017

See other projects for this call

Sub call

H2020-SC1-2017-Two-Stage-RTD

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Net EU contribution
€ 2 399 915,96
Address
Josef-schneider-strasse 2
97080 Wurzburg
Germany

See on map

Region
Bayern Unterfranken Würzburg, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (11)

OSPEDALE SAN RAFFAELE SRL
Italy
Net EU contribution
€ 603 125,00
Address
Via Olgettina 60
20132 Milano

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

UNIVERSITA VITA-SALUTE SAN RAFFAELE
Italy
Net EU contribution
€ 145 000,00
Address
Via Olgettina 58
20132 Milano

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSIDAD DE NAVARRA
Spain
Net EU contribution
€ 512 375,00
Address
Campus Universitario Edificio Central
31080 Pamplona

See on map

Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
France
Net EU contribution
€ 250 272,50
Address
Avenue Oscar Lambret 2
59037 Lille

See on map

Region
Hauts-de-France Nord-Pas de Calais Nord
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Germany
Net EU contribution
€ 342 875,00
Address
Paul-ehrlich-strasse 51-59
63225 Langen

See on map

Region
Darmstadt Offenbach, Landkreis
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Non-EU contribution
€ 0,00
DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH
Germany
Net EU contribution
€ 848 000,00
Address
Friedrich Ebert Strasse 107
68167 Mannheim

See on map

Region
Baden-Württemberg Karlsruhe Mannheim, Stadtkreis
Activity type
Research Organisations
Non-EU contribution
€ 0,00
MYELOMA PATIENTS EUROPE AISBL
Belgium
Net EU contribution
€ 115 625,00
Address
Avenue Louise 143 4
1050 Bruxelles

See on map

Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Other
Non-EU contribution
€ 0,00
NBE-THERAPEUTICS AG

Participation ended

Switzerland
Net EU contribution
€ 99 436,54
Address
Hochbergerstrasse 60c Technologie Park Basel
4057 Basel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
T-CURX GMBH
Germany
Net EU contribution
€ 453 750,00
Address
Friedrich-bergius-ring 15
97076 Wurzburg

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Bayern Unterfranken Würzburg, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
ARTTIC
France
Net EU contribution
€ 152 493,74
Address
39 Rue Des Mathurins
75008 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
ARTTIC INNOVATION GMBH
Germany
Net EU contribution
€ 175 006,26
Address
Oskar-von-miller-ring 29
80333 Munchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00